BACHEM

HALF-YEAR REPORT

2026

FOCUS AND GROWTH

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and production sites in Europe and the US. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

CONTENT

CHF 326.4 MILLION

SALES IN THE FIRST HALF OF THE YEAR

Sales increase driven by clinical projects.

GROWTH

CONFIRMED

35% to 40% sales growth in constant currencies.

CHF 148.4 MILLION

INVESTMENTS

into the global manufacturing network.

MARKET GROWTH

FOR TIDES

driven by new indications and larger patient populations.

1ST HALF-YEAR 2026 IN BRIEF

SALES GROWTH
in percent

4.3

EBITDA MARGIN
in percent

25.4

EARNINGS PER SHARE
in CHF

0.67

SALES
in CHF million



EBITDA
in CHF million



NET INCOME
in CHF million



			Changes in	
	2026	2025	CHF	LC
Sales (in CHF million)	326.4	313.0	+ 4.3%	+ 7.3%
EBITDA (in CHF million)	82.8	91.0	− 9.0%	− 4.2%
EBITDA margin	25.4%	29.1%		
EBIT (in CHF million)	54.1	66.9	− 19.1%	− 13.1%
EBIT margin	16.6%	21.4%		
Net income (in CHF million)	50.3	50.1	+ 0.3%	
Net income margin	15.4%	16.0%		
Earnings per share (in CHF)	0.67	0.67	+ 0.4%	
Cash flow from operating activities (in CHF million)	104.7	86.0	+ 21.7%	
Number of employees (in full-time equivalents)	2 725	2 511[1]		

[1] Value as per December 31, 2025

COMMENT AND OUTLOOK

Bachem grew again in the first half of 2026. However, the costs associated with the growth in the second half of the year are weighing on earnings in the short term. At the same time, the company made targeted investments to expand its capacity for medium-term growth. The implementation of the expansion strategy is proceeding according to plan.

Sales development

The Bachem Group (SIX: BANB) increased sales to CHF 326.4 million in the first half of 2026 (+4.3% compared to the prior-year period: CHF 313.0 million). In local currencies (LC), sales increased by 7.3%.

Profit development

Operating income before depreciation and amortization (EBITDA) amounted to CHF 82.8 million (-9.0%, -4.2% in LC), and operating income (EBIT) was CHF 54.1 million (-19.1%, -13.1% in LC).

As a result, the EBITDA margin was 25.4% (first half of 2025: 29.1%) and the EBIT margin was 16.6% (first half of 2025: 21.4%). In local currencies, the EBITDA margin was 25.9% and the EBIT margin 17.3%.

Net income increased to CHF 50.3 million (+0.3%) with a margin of 15.4% (first half of 2025: 16.0%) due to the positive financial result.

Cost structure

Due to the higher costs associated with the preparation for growth in the second half of 2026, as well as a changed product mix, gross profit was lower than in the prior-year period, amounting to CHF 81.7 million (first half of 2025: CHF 90.1 million). Marketing and sales costs remained unchanged in the first half of the year at CHF 7.9 million (first half of 2025: CHF 7.9 million) and decreased from 2.5% to 2.4% of sales. Bachem continuously invests in process improvements and manufacturing technology in order to further expand its technological leadership. Research and development costs amounted to CHF 6.6 million (first half of 2025: CHF 4.8 million), representing 2.0% of sales (first half of 2025: 1.5%). General administrative costs were CHF 13.5 million (first half of 2025: CHF 11.0 million), accounting for 4.1% of sales (first half of 2025: 3.5%). This includes the ongoing expansion of management functions for the growing organization.

Cost development will continue to be aligned with long-term corporate growth.

Financial result

The financial result led to a net gain of CHF 2.5 million in the first half of the year (first half of 2025: net loss of CHF 10.7 million). A key factor affecting the financial result was the appreciation of the US dollar against the Swiss franc and, consequently, the valuation of loans to subsidiaries denominated in US dollars at holding company level at the reporting date. This led to a net foreign exchange gain of CHF 3.3 million (first half of 2025: net foreign exchange loss of CHF 10.8 million). Interest expense increased by CHF 0.6 million to CHF 0.7 million due to higher financial liabilities.

Income taxes

Income tax expenses amounted to CHF 6.4 million, resulting in a group-wide tax rate of 11.3% (first half of 2025: CHF 6.1 million or 10.8%).

Market situation

The momentum in the peptide market continues, driven by robust demand for therapies targeting large patient populations and the expansion into new therapeutic applications. While the industry has historically focused on manufacturing relatively small volumes, large-scale industrial production is now coming to the forefront. As a result, requirements for production capacity and supply chains are increasing significantly. Substantial investments in capacity, infrastructure, and technological innovation are required. At the same time, improving efficiency across the entire value chain is becoming increasingly important. In this environment, long-term strategic partnerships between manufacturers, customers, and suppliers are a key success factor. Such partnerships provide access to additional production capacity as well as specialized technologies.

The oligonucleotide market is currently still more heavily driven by clinical development programs than by large-scale commercial production volumes. As additional products mature, demand for scalable manufacturing capacity is also expected to increase in this segment. Companies that can combine capacity expansion with technological innovation, process optimization, and efficient manufacturing are likely to be well positioned to benefit from this trend.

Macroeconomic environment and risks
Macroeconomic conditions have become more volatile amid uncertainties in global trade. Bachem is well positioned in this environment, benefiting from several structural advantages. The company's focus on specialized critical APIs for regulated healthcare products makes its offerings difficult to substitute in the near term. In addition, contractual arrangements provide favorable protection against potential tariff effects. Bachem's manufacturing footprint, centered in Switzerland and the United States, together with its ability to internally produce selected starting materials, further mitigates the risk of supply chain disruptions.

Sales by product categories
In the Commercial API category, sales decreased to CHF 133.0 million (first half of 2025: CHF 168.4 million, -21.0%, in LC -19.3%). We expect a stronger contribution in the second half of the year.

In the clinical drug development category (CMC Development), sales increased to CHF 167.5 million (first half of 2025: CHF 123.7 million, +35.4%, in LC: +39.5%) due to a strong pipeline of peptide and oligonucleotide development projects.

The research chemicals and specialties business (Research & Specialties) delivered CHF 25.9 million (first half of 2025: CHF 20.8 million, +24.4%, in LC: +30.5%), in part due to higher sales of peptides for use in cosmetics.

Number of employees
The number of employees grew by 8.5% compared to the end of the previous year, to around 2,725 full-time equivalents. This expansion is related to the ramp up of Building K, and we expect continued growth in our workforce in the second half of the year.

Substantial capacity expansion
In the first half of 2026, CHF 148.4 million was invested, with significant volumes to be invested in the second half of the year. In addition to expansion, Bachem is also continuously optimizing the utilization of existing buildings and facilities to achieve operational improvements.

Bachem's largest facility to date for the production of peptides and oligonucleotides (Building K) was successfully put into operation in 2026 and has already started production of its first commercial GMP products. Concurrently, the facility is being further expanded in stages to unlock additional manufacturing capacity. The successful scale-up of commercial production is a cornerstone of Bachem's long-term growth strategy.

The next expansion phase of the new production site in Sisslerfeld (Eiken, Switzerland) will be realized through a strategic collaboration. Bachem plans to build a large-scale manufacturing facility, which is expected to begin commercial production by 2030.

Bachem continues to invest in its entire network of sites, focusing on site-specific core competencies. In the US, high-volume capacity is being expanded.
Also in the US, Bachem is focusing on promising small-volume clinical projects, while investments in Western Switzerland are aimed at securing the supply of key precursors.

Sustainability
Bachem pursues long-term sustainability targets across the Group, focusing in particular on occupational safety, employee health, energy consumption, and green-house gas emissions. Emissions throughout the value chain (Scope 3) are managed through a comprehensive emissions management framework. In 2025, Bachem submitted science-based climate targets (SBTs), which have since been validated by the Science Based Targets initiative (SBTi) and explicitly address Scope 3 emissions. Bachem continuously enhances its sustainable procurement practices to more effectively integrate sustainability requirements throughout the supply chain.

Cash flow

In the first half of 2026, cash flow from operating activities was CHF 104.7 million (first half of 2025: CHF 86.0 million). Income tax payments resulted in an outflow of CHF 9.3 million (first half of 2025: CHF 7.3 million). A positive effect came from the reduction in trade receivables of CHF 6.1 million, net inflows of CHF 86.2 million from non-current and current prepayments from customers (first half of 2025: CHF 20.6 million), and the increase in trade payables of CHF 20.6 million. An offsetting effect was the growth-related increase in inventory of CHF 80.9 million. In the course of capacity expansion, as well as for ongoing investments, CHF 166.2 million in cash and cash equivalents was used during the reporting period (first half of 2025: CHF 147.0 million). Financial liabilities increased due to capacity expansion by CHF 150.7 million during the reporting period.

A gross total of CHF 67.5 million was distributed as a dividend (previous year: CHF 63.7 million; CHF 30.7 million were paid out and CHF 33.0 million remained as a loan from the related party Ingro Finanz AG). The increase in cash and cash equivalents in the reporting period was thus CHF 20.6 million (first half of 2025: decrease in cash and cash equivalents of CHF 66.1 million). As of June 30, 2026, cash and cash equivalents amounted to CHF 51.6 million (December 31, 2025: CHF 31.0 million).

Equity and liabilities

The equity ratio as of June 30, 2026, was 61.7% (December 31, 2025: 69.2%). Current- and non-current financial liabilities – consisting of a syndicated revolving credit facility, a loan from the related party Ingro Finanz AG, and finance lease liabilities – increased to CHF 208.1 million during the reporting period.

During the reporting period, a syndicated revolving credit facility of CHF 500 million with a maturity of five years and a non-committed option to increase the facility by CHF 150 million was established. As of the reporting date, CHF 175.0 million of this facility had been drawn down.

The loan from the related party Ingro Finanz AG amounted to CHF 33.0 million as of the reporting date (December 31, 2025: CHF 33.0 million).

Finance lease liabilities amounted to CHF 0.1 million (December 31, 2025: CHF 0.1 million). As of June 30, 2026, Bachem had no bilateral bank loans (December 31, 2025: CHF 24.3 million).

Outlook

For 2026, Bachem expects sales growth in local currencies between 35% and 40%. The EBITDA margin in local currencies should be in the low thirties. The company plans to make investments between CHF 350 million and CHF 400 million in 2026.

CONSOLIDATED INCOME STATEMENT

(Unaudited)

in CHF 1 000	Notes	**First half-year 2026**	First half-year 2025
Net sales	6	326 445	312 986
Cost of goods sold		– 244 791	– 222 927
Gross profit		**81 654**	**90 059**
Other income		534	517
Marketing and sales costs		– 7 908	– 7 853
Research and development costs		– 6 586	– 4 752
General administrative costs		– 13 545	– 11 045
Operating income (EBIT)		**54 149**	**66 926**
Financial income	7	3 438	206
Financial expenses	8	– 930	– 10 954
Ordinary income		**56 657**	**56 178**
Extraordinary result	9	0	0
Income before taxes		**56 657**	**56 178**
Income taxes		– 6 387	– 6 077
Net income[1]		**50 270**	**50 101**
Earnings per share (CHF)[2]		**0.67**	**0.67**

[1] The net income is completely attributable to the equity holders of the parent.
[2] There are no options or similar that have a dilutive effect.

The notes on pages 9 to 12 are an integral part of the consolidated interim financial statements.

CONSOLIDATED BALANCE SHEET

(Unaudited)

in CHF 1 000	Notes	June 30, 2026	Dec. 31, 2025
Assets			
Cash and cash equivalents		51 574	30 988
Trade receivables		174 163	179 261
Other current receivables		6 795	5 996
Prepaid expenses and accrued income		16 021	13 152
Current income tax assets		3 067	2 939
Inventories		577 325	494 430
Total current assets		**828 945**	**726 766**
Property, plant and equipment		1 454 327	1 334 008
Intangible assets		30 585	27 941
Deferred tax assets		25 302	20 010
Total non-current assets		**1 510 214**	**1 381 959**
Total assets		**2 339 159**	**2 108 725**
Liabilities and equity			
Trade payables		62 388	41 806
Other current liabilities	10	186 119	245 097
Accrued expenses and deferred income		51 499	47 928
Current income tax liabilities		8 750	13 301
Current financial liabilities	11	208 064	57 322
Total current liabilities		**516 820**	**405 454**
Other non-current liabilities	10	313 188	186 548
Non-current financial liabilities	11	39	70
Deferred tax liabilities		65 313	58 336
Total non-current liabilities		**378 540**	**244 954**
Total liabilities		**895 360**	**650 408**
Share capital		750	750
Retained earnings		935 064	918 533
Offset goodwill		– 1 404	– 1 404
Share premium		569 290	604 404
Own shares		– 2 467	– 3 910
Cumulative translation differences		– 57 434	– 60 056
Total capital and reserves attributable to the equity holders of the company		**1 443 799**	**1 458 317**
Total liabilities and equity		**2 339 159**	**2 108 725**

The notes on pages 9 to 12 are an integral part of the consolidated interim financial statements.

CONSOLIDATED CASH FLOW STATEMENT

(Unaudited)

in CHF 1 000	Notes	**First half-year 2026**	First half-year 2025
Cash flow from operating activities			
Net income		50 270	50 101
Adjustments for:			
Income taxes		6 387	6 077
Depreciation (and amortization)		28 646	16 177
Financial income	7	– 3 438	– 206
Financial expenses	8	930	10 954
Share based payments		1 081	1 014
Loss on sale/scrapping of property, plant and equipment		69	48
Change in other non-current liabilities		126 405	9 260
Income taxes paid		– 9 347	– 7 345
Cash flow from operating activities before changes in net working capital		**201 003**	**86 080**
Change in trade receivables		6 088	58 471
Change in other current receivables, prepaid expenses and accrued income		– 3 575	10 989
Change in inventories		– 80 866	– 42 070
Change in trade payables		20 648	– 40 547
Change in other current liabilities, accrued expenses and deferred income		– 38 627	13 055
Cash flow from operating activities		**104 671**	**85 978**
Cash flow from investing activities			
Investments in property, plant and equipment		– 160 432	– 142 672
Sales of property, plant and equipment		59	2
Investments in intangible assets		– 5 686	– 4 344
Other financial payments and proceeds		– 92	76
Cash flow from investing activities		**– 166 151**	**– 146 938**
Cash flow from financing activities			
Dividends paid	4	– 67 478	– 30 731
Increase in financial liabilities	11	175 000	27 650
Repayment of financial liabilities	11	– 24 289	– 90
Additions of own shares		– 1 013	– 999
Interest paid		– 253	– 118
Cash from financing activities		**81 967**	**– 4 288**
Net effect of currency translation on cash and cash equivalents		99	– 807
Net change in cash and cash equivalents		**20 586**	**– 66 055**
Cash and cash equivalents at the beginning of the year		**30 988**	**95 197**
Cash and cash equivalents at the end of the half-year		**51 574**	**29 142**
Net change in cash and cash equivalents		**20 586**	**– 66 055**

The notes on pages 9 to 12 are an integral part of the consolidated interim financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(Unaudited)

2026 in CHF 1 000	Notes	Share capital	Retained earnings	Offset goodwill	Share premium	Own shares	Cumulative translation differences	Total
Balance at January 1		**750**	**918 533**	**– 1 404**	**604 404**	**– 3 910**	**– 60 056**	**1 458 317**
Net income according to income statement			50 270					**50 270**
Dividends	4		– 33 739		– 33 739			**– 67 478**
Transactions with own shares (net of tax)					– 227	– 786		**– 1 013**
Share based payments					– 1 148	2 229		**1 081**
Cumulative translation differences							2 622	**2 622**
Balance at June 30		**750**	**935 064**	**– 1 404**	**569 290**	**– 2 467**	**– 57 434**	**1 443 799**

2025 in CHF 1 000	Notes	Share capital	Retained earnings	Offset goodwill	Share premium	Own shares	Cumulative translation differences	Total
Balance at January 1		**750**	**801 980**	**– 1 404**	**633 557**	**– 2 074**	**– 41 720**	**1 391 089**
Net income according to income statement			50 101					**50 101**
Dividends	4		– 32 240		– 31 491			**– 63 731**
Transactions with own shares (net of tax)					– 245	– 754		**– 999**
Share based payments					222	792		**1 014**
Cumulative translation differences							– 17 467	**– 17 467**
Balance at June 30		**750**	**819 841**	**– 1 404**	**602 043**	**– 2 036**	**– 59 187**	**1 360 007**

The notes on pages 9 to 12 are an integral part of the consolidated interim financial statements.

SELECTED EXPLANATORY NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1 Accounting policies

Principles of consolidation

These consolidated interim financial statements comprise the unaudited consolidated financial statements of Bachem Holding AG, a company registered in Switzerland, and its subsidiaries for the six-month period ended June 30, 2026.

The consolidated interim financial statements were prepared in accordance with Swiss GAAP FER 31 “Complementary recommendations for listed public companies.” These consolidated interim financial statements do not include all the information and disclosures contained in the annual consolidated financial statements and should therefore be read in conjunction with the consolidated financial statements for the year ended December 31, 2025, which were prepared in accordance with the Swiss Accounting and Reporting Recommendations (Swiss GAAP FER).

Changes in accounting policies

For the reporting year 2026, no changes in accounting policies became effective. The accounting policies used are consistent with those used in the annual consolidated financial statements 2025.

Approval of the interim financial statements

The consolidated interim financial statements were approved for issue by the Board of Directors of Bachem Holding AG on July 21, 2026.

2 Foreign exchange rates

	Income statement average rates		Balance sheet period-end rates	
in CHF	**First half-year 2026**	First half-year 2025	**June 30, 2026**	Dec. 31, 2025
USD	0.79	0.86	0.81	0.79
EUR	0.92	0.94	0.92	0.93
GBP	1.06	1.12	1.07	1.07
JPY (100)	0.50	0.58	0.50	0.51

3 Seasonality

The operating income is subject to fluctuations having no seasonal origin.

4 Dividend distribution

On May 6, 2026, a dividend of CHF 67.5 million, respectively CHF 0.90 per share was distributed for the year 2025 (previous year: CHF 63.7 million, respectively CHF 0.85 per share). In the previous year, CHF 30.7 million of the total dividend were paid out and CHF 33.0 million remained as a loan versus Ingro Finanz AG.

5 Segment reporting

The Bachem Group consists of one reportable segment. The financial information is regularly reported to the Board of Directors at Bachem Group level as a whole. This financial information is used to manage the Bachem Group and measure its performance. This adjustment has no financial impact on the consolidated financial statements of the Bachem Group.

Bachem provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Products and services in the product categories Commercial API, CMC Development and Research & Specialties form the basis for all sales. The companies of the Bachem Group basically manufacture all the above-mentioned products or provide the services.

6 Net sales

The reported net sales consist of the following:

in CHF 1 000	**First half-year 2026**	First half-year 2025
Products and services		
Products	284 528	276 666
Services	41 917	36 320
Total net sales	**326 445**	**312 986**
Product categories		
Commercial API	133 003	168 436
CMC Development	167 521	123 706
Research & Specialties	25 921	20 844
Total net sales	**326 445**	**312 986**
Geographical areas		
Switzerland	36 309	40 656
USA	125 004	107 786
Denmark	48 301	27 903
Ireland	29 754	59 688
United Kingdom	22 905	20 566
Rest of the world	64 172	56 387
Total net sales	**326 445**	**312 986**

Net sales are attributed to the individual countries based on the invoice address of the respective customer.

7 Financial income

in CHF 1 000	**First half-year 2026**	First half-year 2025
Interest income	115	188
Other financial income	1	18
Foreign exchange result	3 322	0
Total financial income	**3 438**	**206**

8 Financial expenses

in CHF 1 000	**First half-year 2026**	First half-year 2025
Interest expenses	– 759	– 122
Other financial expenses	– 171	– 53
Foreign exchange result	0	– 10 779
Total financial expenses	**– 930**	**– 10 954**

9 Extraordinary result

in CHF 1 000	**First half-year 2026**	First half-year 2025
Accrued income from insurance claims	0	11 482
Reversal of impairment of property, plant and equipment	0	7 848
Reduction accrued income from insurance claims due to reversal of impairment	0	– 7 848
Total extraordinary income	**0**	**11 482**
Miscellaneous event-related expenses	0	– 11 482
Impairment of property, plant and equipment	0	0
Total extraordinary expenses	**0**	**– 11 482**
Total extraordinary result	**0**	**0**

In connection with the two insurance claims – the fire at the production site in Vionnaz on November 21, 2023, and the incident on the construction site of Building K in Bubendorf on May 27, 2024 - no additional costs were incurred in the first half of 2026. During the reporting period, the accruals for insurance claims recognized in the balance sheet were reduced by the advance payments received from the insurance company in the amount of CHF 2.0 million.

10 Other current and non-current liabilities

As of June 30, 2026, other current liabilities include, besides various other liabilities, prepayments from customers in the amount of CHF 142.2 million (December 31, 2025: CHF 182.1 million).

Other non-current liabilities consist exclusively of non-current prepayments from customers. For these prepayments, the deliveries and services to be provided are expected in a period of more than 12 months after the balance sheet date.

11 Financial liabilities

As of 30 June 2026, Bachem has a syndicated revolving credit facility with a total volume of CHF 500.0 million, of which CHF 175.0 million had been drawn as of the reporting date (December 31, 2025: n/a). In addition, as of the balance sheet date, there is a loan from the related party Ingro Finanz AG in the amount of CHF 33.0 million (December 31, 2025: CHF 33.0 million), as well as finance lease liabilities of CHF 0.1 million (December 31, 2025: CHF 0.1 million). As of 30 June 2026, Bachem had no bilateral bank loans outstanding (December 31, 2025: CHF 24.3 million).

The syndicated credit facility and the loan from the related party were provided as unsecured business loans in CHF.

The average interest expense amounted to 1.3% p.a. during the reporting period. The interest of the syndicated revolving credit facility is based on SARON plus an interest margin that depends on a financial covenant in the form of a maximum leverage ratio. The Bachem Group complies with this covenant as of June 30, 2026.

The individual tranches of the syndicated credit facility have remaining durations of less than 3 months and the finance leases between 0.5 and 3.5 years. The loan from the related party is of indefinite duration but can be terminated at any time.

12 Contingent liabilities and other commitments

There are no material contingent liabilities or other commitments at the balance sheet date.

13 Events after the balance sheet date

There have been no material events after the balance sheet date.

FINANCIAL CALENDAR

ANNUAL REPORT 2026
March 4, 2027

ANNUAL GENERAL MEETING (BUSINESS YEAR 2026)
April 28, 2027

HALF-YEAR REPORT 2027
July 29, 2027

Forward-looking statements
Forward-looking statements contained herein are qualified in their entirety and are of only limited validity. Investors are cautioned that all forward-looking statements involve risks and uncertainty. There are certain factors that could cause results to differ materially from those anticipated. This includes as well the timing and strength of new product offerings, pricing strategies of competitors, the Group's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs, and changes in the political, social and regulatory framework in which the Group operates, or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis.

IMPRINT

This Half-Year Report is published in German and English.
The German language version is binding.

Publisher
Bachem Holding AG,
Bubendorf, Switzerland

Conception/Design
Linkgroup AG, Zurich

Prepress/Print
Printmedia AG, Zurich

This Half-Year Report is printed on FSC-certified paper.

FSC www.fsc.org MIX Paper from responsible sources FSC® C008549

BACHEM

Switzerland

Investor Relations
Bachem Holding AG
Barbora Blaha
Head Investor Relations
Hauptstrasse 144
4416 Bubendorf
Switzerland
Tel +41 58 595 2021
Fax +41 58 595 2043
ir@bachem.com
www.bachem.com

Bachem Holding AG
Bachem AG
Hauptstrasse 144
4416 Bubendorf
Switzerland
Tel +41 58 595 2021
Fax +41 58 595 2041
sales.ch@bachem.com

Bachem SA
Succursale Vionnaz
Route du Simplon 22
1895 Vionnaz
Switzerland
Tel +41 58 595 3990
Fax +41 58 595 3991
info.bvi@bachem.com

United Kingdom

Bachem (UK) Ltd.
1 Delph Court
Sherdley Business Park
Sullivans Way
St. Helens
Merseyside WA9 5GL
United Kingdom
Tel +44 1744 61 2108
sales.uk@bachem.com

USA

Bachem Americas, Inc.
3132 Kashiwa Street
Torrance, CA 90505
USA
Tel +1 310 539 4171
Fax +1 310 539 9428
US toll-free number:
1-888-4-BACHEM
sales.us@bachem.com

Bachem Americas, Inc.
1271 Avenida Chelsea
Vista, CA 92081
USA
Tel +1 310 539 4171
Fax +1 310 539 9428
US toll-free number:
1-888-4-BACHEM
sales.us@bachem.com